Alison Dennis
Latest From Alison Dennis
The Times They Are A-Changin’: Opportunities In Medtech Regulation For The UK After Brexit
The turn of the year is a chance to reflect on times past and the future, to make resolutions and look ahead to changes for the better. With Brexit in mind, this is the time to prophesize on UK medtech’s immediate future.
The Times They Are A-Changin’: Opportunities In Medtech Regulation For The UK After Brexit
The end of a calendar year is a chance to reflect on times past and the future, to make resolutions and look ahead to changes for the better. With Brexit in mind, the turn of 2020 is a time to prophesize on UK medtech’s immediate future.
Entry into force of UK Bribery Act in sight
Guidance on this important piece of legislation has now been published and the law is set to enter into force in July. Alison Dennis looks at whether the guidance is helpful for medtech companies.
Entry into force of UK Bribery Act in sight
Guidance on this important piece of legislation has now been published and the law is set to enter into force in July. Alison Dennis looks at whether the guidance is helpful for medtech companies.
Entry into force of UK Bribery Act in sight
Guidance on this important piece of legislation has now been published and the law is set to enter into force in July. Alison Dennis looks at whether the guidance is helpful for pharmaceutical companies.
Pharmaceutical Companies: Beware the UK Bribery Act 2010
Alison Dennis urges pharmaceutical companies to review their compliance policies ahead of the Act's entry into force.